721 related articles for article (PubMed ID: 15207620)
41. Biological properties of herpes simplex virus 2 replication-defective mutant strains in a murine nasal infection model.
Jones CA; Taylor TJ; Knipe DM
Virology; 2000 Dec; 278(1):137-50. PubMed ID: 11112490
[TBL] [Abstract][Full Text] [Related]
42. Regions of the herpes simplex virus type 1 latency-associated transcript that protect cells from apoptosis in vitro and protect neuronal cells in vivo.
Ahmed M; Lock M; Miller CG; Fraser NW
J Virol; 2002 Jan; 76(2):717-29. PubMed ID: 11752162
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of herpes simplex virus reactivation by dipyridamole in a mouse model.
Hay KA; Gaydos A; Tenser RB
J Med Virol; 1996 Oct; 50(2):198-203. PubMed ID: 8915888
[TBL] [Abstract][Full Text] [Related]
44. Interrelationship of Primary Virus Replication, Level of Latency, and Time to Reactivation in the Trigeminal Ganglia of Latently Infected Mice.
Matundan HH; Mott KR; Allen SJ; Wang S; Bresee CJ; Ghiasi YN; Town T; Wechsler SL; Ghiasi H
J Virol; 2016 Oct; 90(20):9533-42. PubMed ID: 27512072
[TBL] [Abstract][Full Text] [Related]
45. Transgenic mouse with the herpes simplex virus type 1 latency-associated gene: expression and function of the transgene.
Mador N; Braun E; Haim H; Ariel I; Panet A; Steiner I
J Virol; 2003 Dec; 77(23):12421-9. PubMed ID: 14610166
[TBL] [Abstract][Full Text] [Related]
46. Methods for detecting the HSV-1 LAT anti-apoptosis activity in virus infected tissue culture cells.
Jin L; Perng GC; Brick DJ; Naito J; Nesburn AB; Jones C; Wechsler SL
J Virol Methods; 2004 Jun; 118(1):9-13. PubMed ID: 15158063
[TBL] [Abstract][Full Text] [Related]
47. Expression of herpes virus entry mediator (HVEM) in the cornea and trigeminal ganglia of normal and HSV-1 infected mice.
Kovacs SK; Tiwari V; Prandovszky E; Dosa S; Bacsa S; Valyi-Nagy K; Shukla D; Valyi-Nagy T
Curr Eye Res; 2009 Oct; 34(10):896-904. PubMed ID: 19895317
[TBL] [Abstract][Full Text] [Related]
48. A herpes simplex virus type 1 mutant deleted for gamma34.5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation.
Samoto K; Perng GC; Ehtesham M; Liu Y; Wechsler SL; Nesburn AB; Black KL; Yu JS
Cancer Gene Ther; 2001 Apr; 8(4):269-77. PubMed ID: 11393279
[TBL] [Abstract][Full Text] [Related]
49. ICP0 is required for efficient reactivation of herpes simplex virus type 1 from neuronal latency.
Halford WP; Schaffer PA
J Virol; 2001 Apr; 75(7):3240-9. PubMed ID: 11238850
[TBL] [Abstract][Full Text] [Related]
50. Determination of the DNA target sequence of poorly reactivable strain HSZP of herpes simplex virus type 1 by polymerase chain reaction.
Kúdelová M; Dragún M; Kosovský J; Matis J; Rajcáni J
Acta Virol; 1996 Feb; 40(1):15-21. PubMed ID: 8886093
[TBL] [Abstract][Full Text] [Related]
51. Decreased reporter gene expression during latent infection with HSV LAT promoter constructs.
Margolis TP; Bloom DC; Dobson AT; Feldman LT; Stevens JG
Virology; 1993 Dec; 197(2):585-92. PubMed ID: 8249281
[TBL] [Abstract][Full Text] [Related]
52. Latency of alpha-herpes viruses is accompanied by a chronic inflammation in human trigeminal ganglia but not in dorsal root ganglia.
Hüfner K; Derfuss T; Herberger S; Sunami K; Russell S; Sinicina I; Arbusow V; Strupp M; Brandt T; Theil D
J Neuropathol Exp Neurol; 2006 Oct; 65(10):1022-30. PubMed ID: 17021407
[TBL] [Abstract][Full Text] [Related]
53. The transcriptional activation domain of VP16 is required for efficient infection and establishment of latency by HSV-1 in the murine peripheral and central nervous systems.
Tal-Singer R; Pichyangkura R; Chung E; Lasner TM; Randazzo BP; Trojanowski JQ; Fraser NW; Triezenberg SJ
Virology; 1999 Jun; 259(1):20-33. PubMed ID: 10364486
[TBL] [Abstract][Full Text] [Related]
54. Anti-apoptotic function of a microRNA encoded by the HSV-1 latency-associated transcript.
Gupta A; Gartner JJ; Sethupathy P; Hatzigeorgiou AG; Fraser NW
Nature; 2006 Jul; 442(7098):82-5. PubMed ID: 16738545
[TBL] [Abstract][Full Text] [Related]
55. The abundant latency-associated transcripts of herpes simplex virus type 1 are bound to polyribosomes in cultured neuronal cells and during latent infection in mouse trigeminal ganglia.
Goldenberg D; Mador N; Ball MJ; Panet A; Steiner I
J Virol; 1997 Apr; 71(4):2897-904. PubMed ID: 9060647
[TBL] [Abstract][Full Text] [Related]
56. A herpes simplex virus type 1 mutant expressing a baculovirus inhibitor of apoptosis gene in place of latency-associated transcript has a wild-type reactivation phenotype in the mouse.
Jin L; Perng GC; Mott KR; Osorio N; Naito J; Brick DJ; Carpenter D; Jones C; Wechsler SL
J Virol; 2005 Oct; 79(19):12286-95. PubMed ID: 16160155
[TBL] [Abstract][Full Text] [Related]
57. The product of a 1.9-kb mRNA which overlaps the HSV-1 alkaline nuclease gene (UL12) cannot relieve the growth defects of a null mutant.
Martinez R; Shao L; Bronstein JC; Weber PC; Weller SK
Virology; 1996 Jan; 215(2):152-64. PubMed ID: 8560762
[TBL] [Abstract][Full Text] [Related]
58. Vaccination with herpes simplex virus type 1 glycoprotein K impairs clearance of virus from the trigeminal ganglia resulting in chronic infection.
Ghiasi H; Cai S; Nesburn AB; Wechsler SL
Virology; 1996 Oct; 224(1):330-3. PubMed ID: 8862430
[TBL] [Abstract][Full Text] [Related]
59. A replication competent HSV-1(McKrae) with a mutation in the amino-terminus of glycoprotein K (gK) is unable to infect mouse trigeminal ganglia after cornea infection.
Saied AA; Chouljenko VN; Subramanian R; Kousoulas KG
Curr Eye Res; 2014 Jun; 39(6):596-603. PubMed ID: 24401006
[TBL] [Abstract][Full Text] [Related]
60. Point mutations in herpes simplex virus type 1 oriL, but not in oriS, reduce pathogenesis during acute infection of mice and impair reactivation from latency.
Balliet JW; Schaffer PA
J Virol; 2006 Jan; 80(1):440-50. PubMed ID: 16352568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
